Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Receivables (2019 - 2025)

Historic Receivables for Bicycle Therapeutics (BCYC) over the last 7 years, with Q1 2025 value amounting to $46.4 million.

  • Bicycle Therapeutics' Receivables changed N/A to $46.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $46.4 million, marking a year-over-year change of. This contributed to the annual value of $35.7 million for FY2024, which is 4831.32% up from last year.
  • Bicycle Therapeutics' Receivables amounted to $46.4 million in Q1 2025.
  • Over the past 5 years, Bicycle Therapeutics' Receivables peaked at $76.5 million during Q1 2023, and registered a low of $1.0 million during Q4 2021.
  • Moreover, its 5-year median value for Receivables was $25.2 million (2022), whereas its average is $31.8 million.
  • Its Receivables has fluctuated over the past 5 years, first crashed by 9316.61% in 2021, then surged by 202070.0% in 2022.
  • Over the past 5 years, Bicycle Therapeutics' Receivables (Quarter) stood at $1.0 million in 2021, then soared by 2020.7% to $21.2 million in 2022, then rose by 13.35% to $24.0 million in 2023, then skyrocketed by 48.31% to $35.7 million in 2024, then soared by 30.07% to $46.4 million in 2025.
  • Its Receivables stands at $46.4 million for Q1 2025, versus $35.7 million for Q4 2024 and $46.7 million for Q2 2024.